Cannabigerol for Psychological and Physiological Effects

(CBG Trial)

Overseen By Carrie Cuttler Dr. Cuttler, Ph.D., Psychology

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington State University

Disqualifiers: Psychiatric disorders, Neurological disorders, Diabetes, others

Compensation: Varies

Number of Visits: 5

100 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to examine the acute effects of cannabigerol (CBG) on various psychological (e.g., anxiety, stress, mood, memory, impairment, intoxication, side effects) and physiological (blood pressure, cortisol, heart rate variability, electrodermal activity, pain tolerance, temperature) outcomes. Further, potential side effects of CBG (sleepiness/fatigue, dry mouth/eyes, increased appetite, and dizziness nausea) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What evidence supports the effectiveness of the drug Cannabigerol (CBG) for psychological and physiological effects?

Research suggests that CBG may help with anxiety, chronic pain, depression, and insomnia, with many users reporting improvements over conventional medicines. It also shows potential for treating neurological disorders and inflammatory conditions, although more studies are needed to confirm these benefits. ^{1 2 3 4 5}

Is Cannabigerol (CBG) safe for human use?

Current research suggests that Cannabigerol (CBG) is generally safe for human use, with most users reporting no adverse effects. Some minor side effects like dry mouth, sleepiness, and increased appetite have been noted, but withdrawal symptoms are rare. ^{1 2 3 4 5}

How is the drug Cannabigerol (CBG) unique compared to other treatments?

Cannabigerol (CBG) is unique because it interacts with specific receptors in the body differently than other cannabinoids like THC and CBD, showing potential for treating neurological disorders and inflammation without psychoactive effects. It is also being explored for its anti-anxiety, neuroprotective, and pain-relieving properties, making it a promising option for conditions that require a multi-faceted approach. ^{1 2 3 4 5}

Eligibility Criteria

This trial is for individuals interested in participating in a study to assess the effects of cannabigerol (CBG), a compound found in cannabis. There are no specific conditions listed, so participants may be from the general population.

Inclusion Criteria

Fluent in English

I am over 21 years old.

Exclusion Criteria

Illiterate

I have a history of low blood pressure.

Pregnant or breastfeeding

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

1 visit (virtual)

Baseline Assessment and CBG/Placebo Administration

Participants undergo baseline assessments and are administered either CBG or placebo

2.5 hours

2 visits (in-person)

Testing Session 1

Participants complete various psychological and physiological assessments after CBG/placebo administration

2.5 hours

1 visit (in-person)

Washout Period

Participants undergo a one-week washout period before the second testing session

1 week

Testing Session 2

Participants complete a second round of assessments with the opposite product (CBG or placebo)

2.5 hours

1 visit (in-person)

Follow-up

Participants are monitored for any delayed effects or side effects post-study

1-2 weeks

Treatment Details

Interventions

• Cannabigerol (CBG)

Trial Overview The study is testing how CBG affects psychological aspects like anxiety, mood, and memory, as well as physiological responses such as blood pressure and heart rate. Participants will receive either CBG or a placebo to compare outcomes.

Participant Groups

Group I: CBG Arm Experimental Treatment 1 Intervention

Participants in this arm will receive CBG

Group II: Placebo Arm Placebo Group 1 Intervention

Participants in this arm will receive a placebo

Who Is Running the Clinical Trial?

Washington State University

Lead Sponsor

Trials

114

Recruited

58,800+

Findings from Research

Cannabigerol (CBG), a compound derived from Cannabis sativa L., shows promising therapeutic potential due to its wide range of biological activities, including anti-inflammatory, antibacterial, and neuromodulatory effects.

CBG's ability to interact with G-protein-coupled receptors suggests it could be useful in treating various diseases that require complex pharmacotherapy, making it a candidate for future therapeutic approaches.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Origin and Biomedical Relevance of Cannabigerol. Jastrząb, A., Jarocka-Karpowicz, I., Skrzydlewska, E.[2022]

Cannabigerol (CBG) is a non-psychoactive cannabinoid that shows promise for various therapeutic applications, including reducing intraocular pressure and exhibiting anti-inflammatory and anti-tumoral effects, based on pre-clinical studies.

CBG acts as a partial agonist at cannabinoid receptors and interacts with other receptors, suggesting it could be a valuable component in developing treatments for conditions like anxiety and neuroprotection.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. Calapai, F., Cardia, L., Esposito, E., et al.[2022]

Cannabigerol (CBG) shows potential therapeutic benefits for neurological disorders and inflammatory bowel disease, with unique interactions at cannabinoid receptors and other receptors like α-2 adrenoceptors and 5-HT1A.

Despite its promising effects, CBG is largely unregulated and under-researched compared to other cannabinoids like CBD, highlighting the need for further studies to understand its safety and efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Pharmacological Case for Cannabigerol. Nachnani, R., Raup-Konsavage, WM., Vrana, KE.[2021]

Cannabigerol (CBG) effectively reduces mechanical hypersensitivity in mice with cisplatin-induced peripheral neuropathy, suggesting its potential as a treatment for neuropathic pain.

The anti-nociceptive effects of CBG are mediated through specific receptors, as its efficacy was blocked by α2-adrenergic and CB1/CB2 receptor antagonists, but not by TRPV1 antagonists, indicating a targeted mechanism of action.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. Sepulveda, DE., Morris, DP., Raup-Konsavage, WM., et al.[2022]

A survey of 127 CBG-predominant cannabis users revealed that most use it for medical purposes, particularly for treating anxiety, chronic pain, depression, and insomnia, with many reporting significant improvements in their conditions.

The study found a favorable safety profile for CBG, with 44% of users reporting no adverse effects and only a small percentage experiencing mild symptoms, suggesting that CBG-predominant cannabis may be a viable alternative to conventional medications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Russo, EB., Cuttler, C., Cooper, ZD., et al.[2023]

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

The Origin and Biomedical Relevance of Cannabigerol. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

The Pharmacological Case for Cannabigerol. [2021]

4. England pubmed.ncbi.nlm.nih.gov

Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. [2023]